Literature DB >> 20200404

The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation.

Sandra Beer-Hammer1, Eva Zebedin, Max von Holleben, Judith Alferink, Bernhard Reis, Philipp Dresing, Daniel Degrandi, Stefanie Scheu, Emilio Hirsch, Veronika Sexl, Klaus Pfeffer, Bernd Nürnberg, Roland P Piekorz.   

Abstract

Class I PI3K-dependent signaling regulates cell proliferation, differentiation, and survival. Analysis of gene-deficient mice revealed specific roles for the hematopoietically expressed PI3K catalytic subunits, p110gamma and p110delta, in development and function of T and B lymphocytes. However, the functional redundancy between these two PI3K isoforms in the B cell lineage remains unclear. Here, we demonstrate that p110delta and p110gamma are expressed in B cells at early developmental stages. Normal B cell differentiation requires both isoforms, as p110gamma/p110delta double deficiency causes an increased percentage of CD43(hi)/B220(+)/CD19(-) cells as compared with single deficiency. Interestingly, initial transformation efficiency of B cell precursors was strongly reduced in double-deficient cells following transformation by p185 bcr-abl or v-abl oncogenes as compared with single-deficient cells. The requirement of p110gamma and p110delta in B cell development is underlined by reduced splenic B cell numbers of p110gamma/p110delta double-deficient mice and of lethally irradiated wild-type mice reconstituted with double-deficient BM. Moreover, the peripheral maintenance of p110gamma/p110delta double-deficient T and B cells was highly impaired following adoptive transfer of double-deficient splenocytes into wild-type mice. Functionally, LPS stimulation of splenocytes revealed proliferation defects resulting in decreased survival of p110gamma/p110delta double-deficient B cells, which correlated with impaired induction of D-type cyclins and Bcl-X(L). Surprisingly, this was not observed when purified B cells were analyzed, indicating a contribution of likely cell-extrinsic factor(s) to the impaired proliferation of double-deficient B cells. Thus, we provide novel evidence that p110gamma and p110delta have overlapping and cell-extrinsic roles in the development, peripheral maintenance, and function of B cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20200404     DOI: 10.1189/jlb.0809585

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  30 in total

Review 1.  Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation.

Authors:  G V Baracho; A V Miletic; S A Omori; M H Cato; R C Rickert
Journal:  Curr Opin Immunol       Date:  2011-02-01       Impact factor: 7.486

2.  The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Authors:  R Thijssen; J Ter Burg; G G W van Bochove; M F M de Rooij; A Kuil; M H Jansen; T W Kuijpers; J W Baars; A Virone-Oddos; M Spaargaren; C Egile; M H J van Oers; E Eldering; M J Kersten; A P Kater
Journal:  Leukemia       Date:  2015-09-04       Impact factor: 11.528

3.  Macrophage Phosphoproteome Analysis Reveals MINCLE-dependent and -independent Mycobacterial Cord Factor Signaling.

Authors:  Madlen Hansen; Julian Peltier; Barbara Killy; Bushra Amin; Barbara Bodendorfer; Anetta Härtlova; Sebastian Uebel; Markus Bosmann; Jörg Hofmann; Christian Büttner; Arif B Ekici; Mario Kuttke; Henrik Franzyk; Camilla Foged; Sandra Beer-Hammer; Gernot Schabbauer; Matthias Trost; Roland Lang
Journal:  Mol Cell Proteomics       Date:  2019-01-11       Impact factor: 5.911

Review 4.  PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.

Authors:  Lomon So; David A Fruman
Journal:  Biochem J       Date:  2012-03-15       Impact factor: 3.857

5.  The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.

Authors:  Faruk Ramadani; Daniel J Bolland; Fabien Garcon; Juliet L Emery; Bart Vanhaesebroeck; Anne E Corcoran; Klaus Okkenhaug
Journal:  Sci Signal       Date:  2010-08-10       Impact factor: 8.192

Review 6.  Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases - potentially novel therapeutic targets.

Authors:  Yoshihiro Ito; Jonathan R Hart; Peter K Vogt
Journal:  Expert Opin Ther Targets       Date:  2018-09-24       Impact factor: 6.902

7.  Different inhibition of Gβγ-stimulated class IB phosphoinositide 3-kinase (PI3K) variants by a monoclonal antibody. Specific function of p101 as a Gβγ-dependent regulator of PI3Kγ enzymatic activity.

Authors:  Aliaksei Shymanets; Oscar Vadas; Cornelia Czupalla; Jaclyn LoPiccolo; Michael Brenowitz; Alessandra Ghigo; Emilio Hirsch; Eberhard Krause; Reinhard Wetzker; Roger L Williams; Christian Harteneck; Bernd Nürnberg
Journal:  Biochem J       Date:  2015-07-01       Impact factor: 3.857

Review 8.  The role of PI3Kγ in the immune system: new insights and translational implications.

Authors:  Stephen M Lanahan; Matthias P Wymann; Carrie L Lucas
Journal:  Nat Rev Immunol       Date:  2022-03-23       Impact factor: 53.106

9.  The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.

Authors:  Edward Banham-Hall; Menna R Clatworthy; Klaus Okkenhaug
Journal:  Open Rheumatol J       Date:  2012-09-07

10.  The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.

Authors:  Samantha D Pauls; Sandrine T Lafarge; Ivan Landego; Tingting Zhang; Aaron J Marshall
Journal:  Front Immunol       Date:  2012-08-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.